MedTrace Logo

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

NCT04352361 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2020-07-07

No results posted yet for this study

Summary

Ascending oral single-dose study to evaluate the safety and pharmacokinetics of TVB- 2640 tablets in the Chinese healthy population.

Conditions

  • Healthy

Interventions

DRUG

TVB-2640

TVB-2640 tablets (25mg/50mg/75mg) one tablet at a time, once per day.

DRUG

Placebo

Oral, matching number of placebo Tablets with active arm.

Sponsors & Collaborators

  • Ascletis Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yahong Chen, MD · Ascletis Pharmaceuticals Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-02
Primary Completion
2020-04-29
Completion
2020-04-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04352361 on ClinicalTrials.gov